Search results
Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
Investor's Business Daily· 3 hours agoRegeneron stock is forming a flat base with a buy point at 998.33, according to MarketSurge. That's...
AstraZeneca’s Fasenra: Approval for asthma may initiate COPD approval
Pharmaceutical Technology via Yahoo Finance· 3 days agoKey opinion leaders (KOLs) interviewed by GlobalData have expressed mixed opinions about Fasenra,...
Earnings call: Pulmonx sees 30% sales boost in Q1, eyes $84M annual target By Investing.com
Investing.com· 8 hours agoPulmonx Corporation (ticker: LUNG) reported a robust start to 2024 with a 30% increase in worldwide...
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
WFRV 5 Green Bay· 1 day agoSociety (ATS) 2024 International Conference taking place May 12-22 in San Diego. "We look forward to presenting encouraging data from our Phase 2a COURSE trial in COPD with ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 12 hours agoPDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
Motley Fool via Yahoo Finance· 7 hours ago(Regeneron shares the rights to...injections per year without sacrificing efficacy, an obvious...
Q1 2024 Pulmonx Corp Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 7 hours agoAs I look ahead, I'm excited to leverage the expertise of our entire team whose collective experience in interventional pulmonology and dedication to our mission to deliver on our commitments ...
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings: Challenges and Opportunities Amidst ...
GuruFocus.com via Yahoo Finance· 6 hours agoRegeneron continues to advance its pipeline with several potential regulatory approvals on the...
Regeneron’s stock dips premarket after earnings fall short of estimates
Market Watch· 8 hours agoAdjusted per-share earnings came to $9.55, below the $10.20 FactSet consensus. Revenue fell 1% to...
Brovana side effects: What they are and how to manage them
Medical News Today· 1 day agoBrovana (arformoterol tartrate) is a brand-name medication that’s prescribed for chronic obstructive...
